|
November 2003 (v03-n11) |
|
- Main Story
- pgs. 1-14 Aphton Pharmaceuticals
- Macro Market Commentary
- pgs. 15-17
- Biotech Monthly Coverage Update
- pg. 18-22
- NIBM Model Portfolio
- pg. 23
- (Full outline below...)
|
 |
|
|
Aphton (APHT) is
a company with a unique way of targeting hormones and peptides that
contribute to conditions such as cancer, ulcers, reflux disease, and
pregnancy. Aphton has three products in clinical trials, but financial
constraints have caused it to narrow its focus to G17DT, its lead drug
treating pancreatic and gastric cancers. |
 |
|
| Aphton is still developing
an effective investor relations effort. |
Subscriber direct access |
|
|
This means the company
is under-followed by Wall Street. Good results from a recent Phase III
trial barely moved the stock. With a market cap at publication of around
$160M, this might just be an undervalued bit of coal nearly ready to
become a diamond. |
|
|
| The following is an outline of this issue of
the NIBM Newsletter. |
|
|
- Main Story - Working through Aphton's
issues
- Introduction
- Table: Basic facts on Introgen
- Disclosures
- Investment case
-
Gastrointestinal tract
- Gastrin in the wild
-
- G17DT
- The molecule
- Mechanism of
action
- The bad news
- Indications
- Pancreatic cancer
- Gastric
cancer
- GERD
- Clinical
trials
- Table: Recent/Ongoing G17DT
clinical trials
- Phase III monotherapy for
pancreatic cancer (PC-6)
- Table: G17DT as monotherapy
- all 154 patients
- Table: G17DT as monotherapy -
"responders" only
- Sidebar: Gemcitabine
comparison
- Phase II gastric cancer
- Table: Comparison of two
gastric cancer trials at ASCO 2003
- Phase III gemcitabine combo
comparison trial (PC-4)
- Regulatory pathway
- GnRH Pharmaccine
- Anti-hCG vaccine
- Preclinical
- Partnerships
- Aventis
- GlaxoSmithKline
- WHO
- Financings & Debt
- September 2003 offering
- Series A
- 2003 senior convertible notes
- April 4th notes
- June 12th notes
- February 2003 stock offerings
Table: Aphton selected milestones
- What can go Wrong
Macro Market Commentary - "October
comes in November"
Biotech Monthly Coverage Updates
- Pharmos
- Table: Basic facts for Q3-2003
- Table: Pharmos selected milestones
- Genta
- Nabi
- Dendreon
- Table: Biotech Monthly's Provenge
partnership projections
- Indevus
- Adolor
- Sonus
- Introgen
- Patent
- New trials
- Onyx Pharmaceuticals
- Melanoma data
- RCC update
- Table: RCC subgroup, subset of
evaluable patients only
NIBM Model Portfolio Performance |
|
|
| |
|
|
 |
|
|
|
|
 |
|
|
|
|
|
|
|
|
|
|
